Document is current
Any future updates will be listed below
-
Authors
Hong, Cheng William
Cunha, Guilherme M.
Yokoo, Takeshi
Roudenko, Alexandra
Kelm, Zachary S.
Fung, Alice
Bashir, Mustafa R.
Lewis, Sara
Santillan, Cynthia
Marks, Robert
Sirlin, Claude B.
Fowler, Kathryn J.
Chernyak, Victoria
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01 DK135951, U01 DK130190, U01 DK061734, U01 FD007773, R43 DK135225, R43 EB034626, FNIH 20192423, R01 DK088925, R01 DK106419, and R01 DK110096)
- License Information
-
More Information
Article History
Received: 2 September 2024
Revised: 30 October 2024
Accepted: 2 November 2024
First Online: 30 November 2024
Declarations
:
: Dr. Santillan is a consultant for Alimentiv Inc. and Clario Clinical Research. Dr. Marks is a consultant for Guerbet LLC. Dr. Sirlin reports payment to institution for research grants from ACR, Bayer, Foundation of NIH, GE, Gilead, Pfizer, Philips, Siemens, V Foundation; payment to institution for lab service agreements with OrsoBio, Enanta, Gilead, ICON, Intercept, Nusirt, Shire, Synageva, Takeda; payment to institution for institutional consulting for BMS, Exact Sciences, IBM-Watson, Pfizer; Personal consulting for Altimmune, Ascelia Pharma, Blade, Boehringer, Epigenomics, Guerbet, and Livivos; payment to self for royalties and/or honoraria from Medscape and Wolters Kluwer; ownership of stock options in Livivos; unpaid advisory board position in Quantix Bio; executive position for Livivos (Chief Medical Officer, unsalaried position with stock options and stock) through June 28, 2023; Principal Scientific Advisor to Livivos (unsalaried position with stock options and stock) since June 28, 2023; support for attending meetings and/or travel from Fundacion Santa Fe, Congreso Argentino de Diagnóstico por Imágenes, Stanford, Jornada Paulista de Radiologia, Ascelia Pharma, RSNA, Sociedad Radiológica de Puerto Rico, Hospital Español Auxilio Mutuo de Puerto Rico; member (no payment) of Data Safety Monitoring board for National Cancer Institute funded Early Detection Research Network; equipment loans to institution from Butterfly, GE, Siemens, and Mayo; provision of contrast material to institution from Bayer. Dr. Sirlin receives funding from R01 DK135951, U01 DK130190, U01 DK061734, U01 FD007773, R43 DK135225, R43 EB034626, FNIH 20192423, R01 DK088925, R01 DK106419, and R01 DK110096.
